Page 121 - 《中国药房》2022年6期

120：109437. vival in non-small cell lung cancer：an original cohort
[ 8 ] SI X Y，SONG P，NI J，et al. Management of immune study[J]. Cancer Immunol Immunother，2021，70（7）：
checkpoint inhibitor-related adverse events：a review of 2023-2033.
case reports[J]. Thorac Cancer，2020，11（3）：498-504. [20] ZHANG M，RODRIGUES A J，POLLOM E L，et al. Im-
[ 9 ] LEE D J，LEE H J，Jr，FARMER J R，et al. Mechanisms proved survival and disease control following pembroli-
driving immune-related adverse events in cancer patients zumab-induced immune-related adverse events in high
treated with immune checkpoint inhibitors[J]. Curr Cardiol PD-L1 expressing non-small cell lung cancer with brain
Rep，2021，23（8）：98. metastases[J]. J Neurooncol，2021，152（1）：125-134.
[10] HORVAT T Z，ADEL N G，DANG T O，et al. Immune- [21] ZHOU Y W，XIA R L，XIAO H L，et al. Thyroid function
related adverse events，need for systemic immunosuppres- abnormality induced by PD-1 inhibitors have a positive
sion，and effects on survival and time to treatment failure impact on survival in patients with non-small cell lung
in patients with melanoma treated with ipilimumab at me- cancer[J]. Int Immunopharmacol，2021，91：107296.
morial Sloan Kettering cancer center[J]. J Clin Oncol， [22] ASO M，TOI Y，SUGISAKA J，et al. Association between
2015，33（28）：3193-3198. skin reaction and clinical benefit in patients treated with
[11] DUPONT R，BÉRARD E，PUISSET F，et al. The progno- anti-programmed cell death 1 monotherapy for advanced
stic impact of immune-related adverse events during anti- non-small cell lung cancer[J]. Oncologist，2020，25（3）：
PD1 treatment in melanoma and non-small-cell lung can- e536-e544.
cer：a real-life retrospective study[J]. Oncoimmunology， [23] BALDINI E，LUNGHI A，CORTESI E，et al. Immune-re-
2019，9（1）：1682383. lated adverse events correlate with clinical outcomes in
[12] 艾飞玲，胡葵茹，石钰霖，等.基于纽卡斯尔-渥太华量表 NSCLC patients treated with nivolumab：the Italian NSCLC
对中国吸烟队列研究文献的质量评价[J].中华疾病控制 expanded access program[J]. Lung Cancer，2020，140：
杂志，2021，25（6）：722-729. 59-64.
[13] 皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评 [24] BOUHLEL L，DOYEN J，CHAMOREY E，et al. Occur-
价系统：通用不良反应术语标准4.0版[J].肿瘤，2012，32 rence and number of immune-related adverse events are
（2）：142-144. independently associated with survival in advanced
[14] CHEN X L，NIE J，DAI L，et al. Immune-related adverse non-small-cell lung cancer treated by nivolumab[J]. Bull
events and their association with the effectiveness of PD-1/ Cancer，2020，107（9）：946-958.
PD-L1 inhibitors in non-small cell lung cancer：a real- [25] CORTELLINI A，FRIEDLAENDER A，BANNA G L，et
world study from China[J]. Front Oncol，2021，11： al. Immune-related adverse events of pembrolizumab in a
607531. large real-world cohort of patients with NSCLC with a
[15] CALLEJO A，FRIGOLA J，IRANZO P，et al. Interrela- PD-L1 expression ≥50％ and their relationship with clini-
tions between patients’clinicopathological characteristics cal outcomes[J]. Clin Lung Cancer，2020，21（6）：498-508.
and their association with response to immunotherapy in a e2.
real-world cohort of NSCLC patients[J]. Cancers，2021，13 [26] CUI P F，HUANG D，WU Z Z，et al. Association of im-
（13）：3249. mune-related pneumonitis with the efficacy of PD-1/
[16] CONDE-ESTÉVEZ D，MONGE-ESCARTÍN I，RÍOS-HOYO PD-L1 inhibitors in non-small cell lung cancer[J]. Ther
A，et al. Prognostic factors and effect on survival of im- Adv Med Oncol，2020，12：1758835920922033.
mune-related adverse events in patients with non-small- [27] HUANG L，LI L，ZHOU Y X，et al. Clinical characteri-
cell lung cancer treated with immune checkpoint blo- stics correlate with outcomes of immunotherapy in advanced
ckage[J]. J Chemother，2021，33（1）：32-39. non-small cell lung cancer[J]. J Cancer，2020，11（24）：
[17] MORIMOTO K，YAMADA T，TAKUMI C，et al. Im- 7137-7145.
mune-related adverse events are associated with clinical [28] HOSOYA K，FUJIMOTO D，MORIMOTO T，et al. Asso-
benefit in patients with non-small-cell lung cancer treated ciation between early immune-related adverse events and
with immunotherapy plus chemotherapy：a retrospective clinical outcomes in patients with non-small cell lung can-
study[J]. Front Oncol，2021，11：630136. cer treated with immune checkpoint inhibitors[J]. Clin
[18] 义维丽，赵文成，黄东宁，等. PD-1单抗治疗非小细胞肺 Lung Cancer，2020，21（4）：e315-e328.
癌相关不良反应及其与疗效的相关性分析[J].中国癌症 [29] LIM S M，KIM S W，CHO B C，et al. Real-world experience
杂志，2021，31（3）：203-211. of nivolumab in non-small cell lung cancer in Korea[J].
[19] THUILLIER P，JOLY C，ALAVI Z，et al. Thyroid dysfunc- Cancer Res Treat，2020，52（4）：1112-1119.
tion induced by immune checkpoint inhibitors is associa- [30] NAQASH A R，RICCIUTI B，OWEN D H，et al. Out-
ted with a better progression-free survival and overall sur- comes associated with immune-related adverse events in

中国药房 2022年第33卷第6期 China Pharmacy 2022 Vol. 33 No. 6 ·751 ·